NO20061322L - Kinazolinderivater som tyrosin kinase inhibitorer - Google Patents
Kinazolinderivater som tyrosin kinase inhibitorerInfo
- Publication number
- NO20061322L NO20061322L NO20061322A NO20061322A NO20061322L NO 20061322 L NO20061322 L NO 20061322L NO 20061322 A NO20061322 A NO 20061322A NO 20061322 A NO20061322 A NO 20061322A NO 20061322 L NO20061322 L NO 20061322L
- Authority
- NO
- Norway
- Prior art keywords
- quinazoline derivatives
- tyrosine kinase
- kinase inhibitors
- manufacture
- formula
- Prior art date
Links
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title abstract 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Ceramic Engineering (AREA)
- Health & Medical Sciences (AREA)
- Manufacturing & Machinery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Structural Engineering (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0321620.7A GB0321620D0 (en) | 2003-09-16 | 2003-09-16 | Quinazoline derivatives |
GB0406163A GB0406163D0 (en) | 2004-03-19 | 2004-03-19 | Quinazoline derivatives |
PCT/GB2004/003923 WO2005026150A1 (fr) | 2003-09-16 | 2004-09-13 | Derives de quinazoline utilises comme inhibiteurs de la tyrosine kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20061322L true NO20061322L (no) | 2006-06-15 |
Family
ID=34315440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20061322A NO20061322L (no) | 2003-09-16 | 2006-03-23 | Kinazolinderivater som tyrosin kinase inhibitorer |
Country Status (25)
Country | Link |
---|---|
US (2) | US7569577B2 (fr) |
EP (1) | EP1667991B1 (fr) |
JP (1) | JP4795952B2 (fr) |
AR (1) | AR045663A1 (fr) |
AT (1) | ATE395346T1 (fr) |
AU (1) | AU2004272348B2 (fr) |
BR (1) | BRPI0414489A8 (fr) |
CA (1) | CA2538884C (fr) |
CO (1) | CO5690594A2 (fr) |
CY (1) | CY1108186T1 (fr) |
DE (1) | DE602004013806D1 (fr) |
DK (1) | DK1667991T3 (fr) |
ES (1) | ES2305844T3 (fr) |
HK (1) | HK1091480A1 (fr) |
HR (1) | HRP20080329T3 (fr) |
IL (1) | IL174261A0 (fr) |
MX (1) | MXPA06002964A (fr) |
NO (1) | NO20061322L (fr) |
PL (1) | PL1667991T3 (fr) |
PT (1) | PT1667991E (fr) |
RU (1) | RU2378268C2 (fr) |
SI (1) | SI1667991T1 (fr) |
TW (1) | TW200519104A (fr) |
UA (1) | UA84167C2 (fr) |
WO (1) | WO2005026150A1 (fr) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
WO2003040108A1 (fr) * | 2001-11-03 | 2003-05-15 | Astrazeneca Ab | Derives quinazoline utilises en tant qu'agents antitumoraux |
GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
KR20070027487A (ko) * | 2003-09-16 | 2007-03-09 | 아스트라제네카 아베 | 퀴나졸린 유도체 |
JP2007505873A (ja) * | 2003-09-16 | 2007-03-15 | アストラゼネカ アクチボラグ | チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
WO2005026156A1 (fr) * | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Derives de quinazoline |
GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
GB0326459D0 (en) * | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
US8017321B2 (en) * | 2004-01-23 | 2011-09-13 | The Regents Of The University Of Colorado, A Body Corporate | Gefitinib sensitivity-related gene expression and products and methods related thereto |
US20080113874A1 (en) * | 2004-01-23 | 2008-05-15 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
WO2005075439A1 (fr) * | 2004-02-03 | 2005-08-18 | Astrazeneca Ab | Derives de quinazoline |
US20080090233A1 (en) * | 2004-05-27 | 2008-04-17 | The Regents Of The University Of Colorado | Methods for Prediction of Clinical Outcome to Epidermal Growth Factor Receptor Inhibitors by Cancer Patients |
US20070232607A1 (en) * | 2004-06-04 | 2007-10-04 | Bradbury Robert H | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
JP4881875B2 (ja) * | 2004-12-14 | 2012-02-22 | アストラゼネカ アクチボラグ | 抗腫瘍剤としてのピラゾロピリミジン化合物 |
GB0504474D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
EP1861094A4 (fr) * | 2005-03-11 | 2014-06-11 | Univ Colorado | Inhibiteurs d'histone deacetylase permettant de sensibiliser des cellules cancereuses aux inhibiteurs du facteur de croissance epidermique |
GB0508715D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
GB0508717D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
WO2007023073A2 (fr) * | 2005-08-22 | 2007-03-01 | Boehringer Ingelheim International Gmbh | Heterocycles bicycliques, produits pharmaceutiques contenant ces composes, leur utilisation et procede pour les preparer |
WO2007034144A1 (fr) * | 2005-09-20 | 2007-03-29 | Astrazeneca Ab | Composes de 4- (ih-indazol-s-yl-amino)-quinazoline utilises comme inhibiteurs des tyrosines kinases erbb associees au recepteur pour traiter le cancer |
WO2007034143A1 (fr) * | 2005-09-20 | 2007-03-29 | Astrazeneca Ab | Derives de quinazoline utilises comme agents anticancereux |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US20100222344A1 (en) * | 2005-12-02 | 2010-09-02 | Astrazeneca Ab | 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors |
JP2009517451A (ja) * | 2005-12-02 | 2009-04-30 | アストラゼネカ アクチボラグ | Erbbチロシンキナーゼの阻害剤として使用されるキナゾリン誘導体 |
US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
KR101434164B1 (ko) * | 2006-09-11 | 2014-08-26 | 쿠리스 인코퍼레이션 | 아연 결합 부분을 함유한 퀴나졸린 계열 egfr 억제제 |
SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
CA2723989C (fr) | 2008-05-13 | 2017-04-25 | Astrazeneca Ab | Sel de fumarate de 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline |
CN102452988B (zh) | 2010-10-27 | 2016-01-27 | 中国科学院化学研究所 | 一种喹唑啉衍生物及其制备方法 |
JP6026441B2 (ja) | 2011-03-04 | 2016-11-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | キナーゼ阻害剤としてのアミノキノリン |
TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基-喹啉類 |
AR092529A1 (es) * | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
EP2958911B1 (fr) | 2013-02-21 | 2017-10-18 | GlaxoSmithKline Intellectual Property Development Limited | Quinazolines en tant qu'inhibiteurs de kinase |
CA3044432A1 (fr) | 2016-11-17 | 2018-05-24 | Board Of Regents, The University Of Texas System | Composes a activite antitumorale contre des cellules cancereuses porteuses de mutations egfr ou her2 exon 20 |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3812257A (en) * | 1972-04-07 | 1974-05-21 | Sumitomo Chemical Co | Uricosuric agent |
US3971783A (en) * | 1973-03-07 | 1976-07-27 | Pfizer Inc. | 4-Aminoquinazoline derivatives as cardiac stimulants |
US4335127A (en) * | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
KR910006138B1 (ko) | 1986-09-30 | 1991-08-16 | 에자이 가부시끼가이샤 | 환상아민 유도체 |
US5411963A (en) | 1988-01-29 | 1995-05-02 | Dowelanco | Quinazoline derivatives |
US4921863A (en) * | 1988-02-17 | 1990-05-01 | Eisai Co., Ltd. | Cyclic amine derivatives |
WO1992020642A1 (fr) | 1991-05-10 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Composes aryle et heteroaryle bis monocycliques et/ou bicycliques qui inhibent la tyrosine kinase d'un recepteur du egf et/ou du pdgf |
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
EP0585371B1 (fr) | 1991-05-20 | 2002-04-17 | Rhone-Poulenc Rorer International (Holdings) Inc. | Composes oligomeres aromatiques utilises comme imitateurs de macromolecules bioactives |
US5441963A (en) * | 1991-12-20 | 1995-08-15 | Merrell Dow Pharmaceuticals | Potentiation of NMDA antagonists |
AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
US5395846A (en) | 1993-06-25 | 1995-03-07 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Amino Bi- and tri-carbocyclic aklane bis-aryl squalene synthase inhibitors |
CA2148260A1 (fr) | 1993-09-10 | 1995-03-16 | Yasutaka Takase | Composes a base de quinazoline |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
WO1996033977A1 (fr) | 1995-04-27 | 1996-10-31 | Zeneca Limited | Derives de quinazoline |
GB9508537D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508535D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
GB9515975D0 (en) | 1995-08-04 | 1995-10-04 | Zeneca Ltd | Chemical compounds |
EP0862435A4 (fr) | 1995-11-22 | 1999-02-03 | Merck & Co Inc | Inhibiteurs de la farnesyl-proteine transferase |
GB9604311D0 (en) * | 1996-02-29 | 1996-05-01 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase |
US6127366A (en) * | 1995-11-22 | 2000-10-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
US6313127B1 (en) * | 1996-02-02 | 2001-11-06 | Zeneca Limited | Heterocyclic compounds useful as pharmaceutical agents |
HUP9901155A3 (en) | 1996-02-13 | 2003-04-28 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
CA2249446C (fr) | 1996-04-12 | 2008-06-17 | Warner-Lambert Company | Inhibiteurs irreversibles de tyrosine kinases |
GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
AU3766897A (en) | 1996-07-13 | 1998-02-09 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
EP0837063A1 (fr) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | Dérivés de 4-aminoquinazoline |
ES2384551T3 (es) | 1997-03-05 | 2012-07-06 | Sugen, Inc. | Formulaciones para agentes farmacéuticos hidrófobos |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
DE19816983A1 (de) | 1998-04-17 | 1999-10-21 | Boehringer Ingelheim Pharma | Bicyclen, deren Herstellung und deren Verwendung als Arzneimittel |
US6200976B1 (en) * | 1998-04-17 | 2001-03-13 | Boehringer Ingelheim Pharma Kg | Antithrombotic quinoxazolines |
AU5195999A (en) | 1998-08-11 | 2000-03-06 | Takeda Chemical Industries Ltd. | Cyclic amide compounds, process for producing the same, intermediates thereof and herbicides |
DE69924500T2 (de) | 1998-08-21 | 2006-02-09 | Parker Hughes Institute, St. Paul | Chinazolinderivate |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
NZ512189A (en) * | 1998-11-19 | 2003-10-31 | Warner Lambert Co | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4- yl-propoxy)-quinazolin-6-yl]-acrylamide useful as an irreversible inhibitor of tyrosine kinases |
DE19908567A1 (de) | 1999-02-27 | 2000-08-31 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
AU3281600A (en) * | 1999-02-27 | 2000-09-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transsduction mediated by tyrosine kinases |
US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
RS49836B (sr) | 1999-03-31 | 2008-08-07 | Pfizer Products Inc., | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
HUP0201900A3 (en) * | 1999-06-21 | 2003-02-28 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, pharmaceutical compositions containing them, their use and methods for the production thereof |
CN100376567C (zh) * | 1999-11-05 | 2008-03-26 | 阿斯特拉曾尼卡有限公司 | 作为vegf抑制剂的喹唑啉衍生物 |
UA73993C2 (uk) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
DE10040527A1 (de) | 2000-08-18 | 2002-02-28 | Boehringer Ingelheim Pharma | Chinazoline und Verfahren zu ihrer Herstellung |
US6617329B2 (en) * | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
US20020082270A1 (en) * | 2000-08-26 | 2002-06-27 | Frank Himmelsbach | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
US6653305B2 (en) * | 2000-08-26 | 2003-11-25 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
US6740651B2 (en) * | 2000-08-26 | 2004-05-25 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
US6656946B2 (en) * | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
US20030158196A1 (en) * | 2002-02-16 | 2003-08-21 | Boehringer Ingelheim Pharma Gmbh Co. Kg | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors |
US7019012B2 (en) * | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
NZ516873A (en) | 2001-02-12 | 2003-11-28 | Warner Lambert Co | Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage |
WO2002066445A1 (fr) | 2001-02-21 | 2002-08-29 | Mitsubishi Pharma Corporation | Derives de la quinazoline |
US6562319B2 (en) * | 2001-03-12 | 2003-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
WO2002092578A1 (fr) * | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Derives de quinazoline |
EP1396488A1 (fr) * | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Compose heterocyclique condense et son utilisation medicale |
WO2003040108A1 (fr) * | 2001-11-03 | 2003-05-15 | Astrazeneca Ab | Derives quinazoline utilises en tant qu'agents antitumoraux |
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
DE10204462A1 (de) * | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
US6924285B2 (en) * | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
CN1642552B (zh) * | 2002-03-30 | 2010-05-12 | 贝林格尔英格海姆法玛两合公司 | 作为酪氨酸激酶抑制剂的4-(n-苯氨基)-喹唑啉/喹啉 |
US20040044014A1 (en) * | 2002-04-19 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
US20030225079A1 (en) * | 2002-05-11 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy |
AU2003241898A1 (en) * | 2002-06-03 | 2003-12-19 | Mitsubishi Pharma Corporation | PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR |
TW200420542A (en) | 2002-08-23 | 2004-10-16 | Kirin Brewery | A compound having TGF β inhibition activity and a medicinal composition containing the same |
GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
WO2005012290A1 (fr) * | 2003-07-29 | 2005-02-10 | Astrazeneca Ab | Derivees de piperidyl-quinazoline utilises comme inhibiteurs de la tyrosine kinase |
GB0317665D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
JP2007505873A (ja) * | 2003-09-16 | 2007-03-15 | アストラゼネカ アクチボラグ | チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
KR20070027487A (ko) * | 2003-09-16 | 2007-03-09 | 아스트라제네카 아베 | 퀴나졸린 유도체 |
JP2007505878A (ja) * | 2003-09-19 | 2007-03-15 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
BRPI0414735A (pt) * | 2003-09-25 | 2006-11-21 | Astrazeneca Ab | derivado de quinazolina, composto, composição farmacêutica, uso de derivado de quinazolina, método para produzir um efeito anti-proliferativo em um animal de sangue quente, e, processo para a preparação de um derivado de quinazolina |
GB0326459D0 (en) * | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
WO2005075439A1 (fr) * | 2004-02-03 | 2005-08-18 | Astrazeneca Ab | Derives de quinazoline |
WO2005114576A1 (fr) * | 2004-05-21 | 2005-12-01 | Asahi Kasei Kabushiki Kaisha | Dispositif d'évaluation du contenu d'opération |
US20070232607A1 (en) * | 2004-06-04 | 2007-10-04 | Bradbury Robert H | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases |
-
2004
- 2004-09-13 CA CA2538884A patent/CA2538884C/fr not_active Expired - Fee Related
- 2004-09-13 AU AU2004272348A patent/AU2004272348B2/en not_active Ceased
- 2004-09-13 AT AT04768469T patent/ATE395346T1/de not_active IP Right Cessation
- 2004-09-13 DE DE602004013806T patent/DE602004013806D1/de active Active
- 2004-09-13 SI SI200430769T patent/SI1667991T1/sl unknown
- 2004-09-13 PL PL04768469T patent/PL1667991T3/pl unknown
- 2004-09-13 JP JP2006526682A patent/JP4795952B2/ja not_active Expired - Fee Related
- 2004-09-13 RU RU2006112599/04A patent/RU2378268C2/ru not_active IP Right Cessation
- 2004-09-13 BR BRPI0414489A patent/BRPI0414489A8/pt not_active Application Discontinuation
- 2004-09-13 EP EP04768469A patent/EP1667991B1/fr active Active
- 2004-09-13 US US10/573,090 patent/US7569577B2/en not_active Expired - Fee Related
- 2004-09-13 MX MXPA06002964A patent/MXPA06002964A/es active IP Right Grant
- 2004-09-13 UA UAA200604148A patent/UA84167C2/ru unknown
- 2004-09-13 PT PT04768469T patent/PT1667991E/pt unknown
- 2004-09-13 WO PCT/GB2004/003923 patent/WO2005026150A1/fr active IP Right Grant
- 2004-09-13 DK DK04768469T patent/DK1667991T3/da active
- 2004-09-13 ES ES04768469T patent/ES2305844T3/es active Active
- 2004-09-14 TW TW093127785A patent/TW200519104A/zh unknown
- 2004-09-16 AR ARP040103321A patent/AR045663A1/es not_active Application Discontinuation
-
2006
- 2006-03-12 IL IL174261A patent/IL174261A0/en unknown
- 2006-03-23 NO NO20061322A patent/NO20061322L/no not_active Application Discontinuation
- 2006-04-10 CO CO06034940A patent/CO5690594A2/es not_active Application Discontinuation
- 2006-10-31 HK HK06111949A patent/HK1091480A1/xx not_active IP Right Cessation
-
2008
- 2008-07-07 HR HR20080329T patent/HRP20080329T3/xx unknown
- 2008-07-10 CY CY20081100724T patent/CY1108186T1/el unknown
-
2009
- 2009-06-11 US US12/482,620 patent/US20090312343A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20090312343A1 (en) | 2009-12-17 |
TW200519104A (en) | 2005-06-16 |
CA2538884C (fr) | 2010-09-21 |
PT1667991E (pt) | 2008-07-14 |
JP4795952B2 (ja) | 2011-10-19 |
EP1667991B1 (fr) | 2008-05-14 |
EP1667991A1 (fr) | 2006-06-14 |
DK1667991T3 (da) | 2008-08-18 |
DE602004013806D1 (en) | 2008-06-26 |
IL174261A0 (en) | 2006-08-01 |
US20070043009A1 (en) | 2007-02-22 |
AU2004272348A1 (en) | 2005-03-24 |
BRPI0414489A (pt) | 2006-11-14 |
ATE395346T1 (de) | 2008-05-15 |
BRPI0414489A8 (pt) | 2019-01-15 |
CY1108186T1 (el) | 2014-02-12 |
JP2007505872A (ja) | 2007-03-15 |
RU2378268C2 (ru) | 2010-01-10 |
PL1667991T3 (pl) | 2008-12-31 |
HRP20080329T3 (en) | 2008-08-31 |
CO5690594A2 (es) | 2006-10-31 |
RU2006112599A (ru) | 2007-11-10 |
AU2004272348B2 (en) | 2008-09-04 |
ES2305844T3 (es) | 2008-11-01 |
CA2538884A1 (fr) | 2005-03-24 |
SI1667991T1 (sl) | 2008-10-31 |
US7569577B2 (en) | 2009-08-04 |
AR045663A1 (es) | 2005-11-02 |
WO2005026150A1 (fr) | 2005-03-24 |
MXPA06002964A (es) | 2006-06-14 |
HK1091480A1 (en) | 2007-01-19 |
UA84167C2 (ru) | 2008-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20061322L (no) | Kinazolinderivater som tyrosin kinase inhibitorer | |
NO20061323L (no) | Kinazolinderivater | |
NO20061327L (no) | Kinazolinderivater | |
NO20061415L (no) | Kinazolinderivater | |
NO20061743L (no) | Kinazolinderivater | |
HK1087613A1 (en) | Quinazoline derivatives and their use in the treatment of cancer | |
RS20050363A (en) | Chk-,pdk-and akt-inhibitory pyrimidines,their production an use as pharmaceutical agents | |
CY1109681T1 (el) | Υποκατεστημενα παραγωγα κιναζολινης ως αναστολεις των κινασων aurora | |
NO20066081L (no) | Kinazolinderivater som erbB-reseptortyrosinkinaser | |
NO20070514L (no) | Pyrrolotriazin kinase inhibitorer | |
NO20064895L (no) | 6,6-Bisykliske ring-substituerte heterobisykliske protein-kinase inhibitorer | |
IS2855B (is) | 4-anilínókínasólínafleiður sem andfjölgunarefni | |
NO20092737L (no) | Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer | |
NO20081893L (no) | 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft | |
NO20080675L (no) | P38-Map kinaseinhibitorer og metoder for deres anvendelse | |
NO20081952L (no) | Substituerte pyrazolforbindelser | |
NO20073140L (no) | Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser | |
NO20065727L (no) | Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter | |
NO20071320L (no) | Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer. | |
NO20060415L (no) | Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer | |
NO20072747L (no) | Fremgangsmate for fremstilling av indazolforbindelser | |
WO2008078100A3 (fr) | Nouveaux composés | |
NO20023831L (no) | Pyrrol substituert 2-indolinonproteinkinaseinhibitorer | |
DE60319158D1 (de) | Pyrazoloisoquinolinenderivaten als kinase inhibitoren | |
MX2007003104A (es) | Nuevos derivados de ftalazinona, como inhibidores de cinasa aurora-a. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |